By identifying, quantifying, and sequencing CTCs, or by deep -sequencing ctDNA, we can get genetic information specific to the initiation and evolution of PC, which are of great significance for our understanding of PC. Of these, CTCs and ctDNA are what researchers in our institution have been focusing on.
#Jun yu phd john hopkins university free#
In recent years, noninvasive disease monitoring technology has witnessed an extraordinary explosion of research in the field of liquid biopsy since circulating cell free DNA (cfDNA) was first revealed in body fluids by Mandel and Metais in 1948. These promising markers serve as a unique approach for early detection, monitoring and managing disease states. And as advances in exploring the molecular pathology of pancreatic cancer (PC) and developing novel techniques for nucleic acid sequencing, researchers, in the past decades, have conducted numerous studies showing the potential clinical utility of liquid biopsy, such as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and circulating tumor exosomes for various cancers, including PC. Yu: Although incessant efforts from surgeons, radiologists, and chemotherapists have been made to improve the overall survival of patients with pancreatic cancer, few steps have been made toward a satisfying clinical outcome. Jun Yu, Chief Scientist of Division of Hepatobiliary and Pancreas Surgery at Johns Hopkins, to have an interview with us.ĪPC: Could you please share with us the latest research progress of biomarkers in Pancreatic Cancer?ĭr.
During the Forum, AME was honored to have invited Dr. The Forum was spilt into several sessions of various events and activities, including operation videos’ exchange, MDT discussion on challenging cases, keynote speeches, panel discussion and debate. The International HBP Surgery Forum, held every two years, has now become a magnificent gathering for the researchers, whom are related to HBP surgery to communicate their work and ideas. The Forum is organized by The Second Affiliated Hospital Zhejiang University School of Medicine (ZUSAH) and the Zhejiang Anti-Cancer Association. The 4th International HBP Surgery Forum was held in Hangzhou, Zhejiang Province on 14–17 June, 2018. In addition, he serves as a Committee Member of the Clinical Research Review Committee at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is the Principle Investigator of the Pancreatic Cancer Precision Medicine Center of Excellence (PMCoE) at Johns Hopkins. Furthermore, he developed several novel sequencing technologies, including digital Next-Generation Sequencing (dNGS) and Single-cell Next-Generation Sequencing (scNGS), which allows pancreatic circulating tumor cells detectable for mutation burden analysis. He successfully collaborated with other researchers and produced several peer-reviewed publications in some journals with high impact factor, e.g., Nature, Cancer discovery, Gastroenterology, and Clinical Cancer Research. He was trained in the studies of the general surgery and oncology of pancreatic cancer and his work has led to first-author publications in Journal of Clinical Oncology, GUT, Annals of Surgery, and Clinical Cancer Research as well as numerous other papers as a first-author or co-author in the field of pancreatic cancer research. His research focuses on understanding the biology of pancreatic cancer and cystic neoplasms of the pancreas, and on detecting the actionable mutations/pathways for the patients with pancreatic cancer in a personalized therapeutic strategy. Yu received his medical degree from Gannan Medical University in China and a PhD in Surgery and Oncology from Kyushu University School of Medicine in Japan. He is the Chief Scientist of Division of Hepatobiliary and Pancreas Surgery at Johns Hopkins. Jun Yu ( Figure 1), MD, PhD is an Assistant Professor in the Department of Surgery, Division of Hepatobiliary and Pancreas Surgery at the Johns Hopkins University School of Medicine. Received: 04 July 2018 Accepted: 21 July 2018 Published: 23 July 2018.
0 kommentar(er)
